Clinical Scorecard: Impact of Glucagon-like Peptide 1 Receptor Agonists on Clinical Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• GLP1-RAs (semaglutide, liraglutide, tirzepatide) induce significant weight loss (~9.4 to 11.8 kg) after 3 months in patients with IBD and obesity
• Use of GLP1-RAs is associated with lower risk of surgery and hospitalizations in patients with IBD, particularly those with BMI ≥ 30
• GLP1-RAs may provide dual metabolic and anti-inflammatory benefits, potentially improving clinical outcomes in IBD

Guideline-Based Recommendations

Diagnosis

• Diagnose IBD based on established clinical, endoscopic, and histologic criteria
• Assess comorbid obesity and type 2 diabetes mellitus in patients with IBD

Management

• Consider GLP1-RAs for patients with IBD who have obesity and/or T2DM to achieve weight loss and potentially reduce surgery and hospitalization risks
• Continue conventional IBD therapies alongside GLP1-RAs as indicated
• Monitor for potential adverse effects including risk of intestinal obstruction due to delayed motility

Monitoring & Follow-up

• Regularly monitor weight, BMI, and metabolic parameters (eg, HbA1c)
• Assess IBD disease activity and biomarkers such as CRP and fecal calprotectin
• Monitor for gastrointestinal side effects and signs of intestinal obstruction

Risks

• Potential risk of intestinal obstruction related to delayed intestinal motility from GLP1-RAs
• Adverse effects related to GLP1-RAs including gastrointestinal symptoms

Patient & Prescribing Data

Patients with inflammatory bowel disease and coexisting obesity and/or type 2 diabetes mellitus

GLP1-RAs lead to significant weight loss and are associated with reduced risks of surgery and hospitalizations; findings support potential repurposing of GLP1-RAs in IBD management pending prospective trial confirmation

Clinical Best Practices

• Evaluate BMI and metabolic comorbidities in all patients with IBD to identify candidates for GLP1-RA therapy
• Use GLP1-RAs as adjunctive therapy to improve metabolic status and potentially reduce IBD-related complications
• Implement close monitoring for gastrointestinal adverse events and disease activity during GLP1-RA treatment
• Educate patients on the benefits and risks of GLP1-RAs, emphasizing the importance of adherence and reporting symptoms suggestive of obstruction
• Await further prospective clinical trials to confirm efficacy and safety of GLP1-RAs in IBD

References

• PRISMA Guidelines